Griffies Joel D
Animal Dermatology Clinic, Marietta, GA, USA.
Compend Contin Educ Vet. 2013 May;35(5):E3.
Hyperadrenocorticism (HAC) is a common endocrinopathy in dogs. With better recognition of the disease, more cases are being presented to clinicians for management. Mitotane, a 3- to 4-decade-old therapy, remains a viable and useful option for management of this disease. Thorough education and understanding of the drug are important, however, as the learning curve of how to manage its effects can be significant. Trilostane, a newer option for management of HAC, offers a simplified protocol and, often, smoother and faster control of the disease. It also requires a comfortable knowledge of expected outcome and possible adverse effects. With either drug, careful monitoring and client communication are crucial.
肾上腺皮质功能亢进（HAC）是犬类常见的内分泌疾病。随着对该疾病的认识提高，越来越多的病例被送至临床医生处进行治疗。米托坦，一种已有三四十年历史的疗法，仍然是治疗这种疾病的可行且有用的选择。然而，对该药物进行全面的了解和认识很重要，因为掌握如何应对其效果的学习曲线可能很明显。曲洛司坦，一种治疗HAC的较新选择，提供了简化的方案，并且通常能更平稳、快速地控制疾病。它也需要对预期结果和可能的不良反应有充分的了解。使用这两种药物中的任何一种时，仔细监测和与客户沟通都至关重要。
